Syndax Pharmaceuticals Inc. Common Stock (SNDX)
Stock · NASDAQ · Health Care
$12.92as of 10/16/2026
Price chart
Active signals
SNDX Signal Track Record
How signals performed across all stocks →What SNDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +3.3% | 57% | September 16, 2026 |
| Bollinger Band Breakout | 23 | -2.0% | 43% | June 26, 2026 |
| Bollinger Band BreakdownActive now | 20 | +0.4% | 50% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +6.4% | 67% | September 2, 2026 |
| Any 20-session window (baseline) | -0.9% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also dev…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 298
- Website
- syndax.com/
Fundamentals
- 1-day range
- $12.82$13.65
- Market cap
- $1.76B
- P/E (trailing)
- —
- P/E (forward)
- -15.37
- EPS (trailing)
- $-2.52
- Dividend yield
- —
- Beta
- 0.39
- Avg. volume
- 1.65M
How Syndax Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Syndax Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- PRGOPerrigo Company plc Ordinary Shares$16.63▲ 0.91%Market cap $1.74BP/E —$9.23$22.02
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| PRGO Perrigo Company plc Ordinary Shares | $1.74B | — | $16.63 | ▲ 0.91% | $9.23$22.02 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Syndax Pharmaceuticals Suffers Pipeline Blowbenzinga · 10/13/2026
- Claude AI Just Bought These 2 Pharma StocksYahoo · 9/29/2026
- Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data ReleasesSeekingAlpha · 9/28/2026
- Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 ReadoutsSeekingAlpha · 9/25/2026
Insider Activity
Insider Actions →- Michael A. Metzger · July 8, 2026 · Option Exercise32.4K @ $6.38
- Michael A. Metzger · July 8, 2026 · Sale32.4K @ $24.24
- Nicholas A.J. Botwood · June 12, 2026 · Option Exercise31.2K @ $13.82
- Nicholas A.J. Botwood · June 12, 2026 · Sale31.2K @ $18.14
- Nicholas A.J. Botwood · June 11, 2026 · Option Exercise22.5K @ $13.82
- Nicholas A.J. Botwood · June 11, 2026 · Sale34.3K @ $18
- Keith A. Goldan · June 1, 2026 · Sale1.2K @ $18.99
- Michael A. Metzger · June 1, 2026 · Sale6.8K @ $18.99
Institutional Ownership
March 31, 2026
- Total shares held
- 97.23M
- Total value held
- $2.24B
- Institutional holders
- 237
- Unknown8.25M
- Unknown8.05M
- Unknown5.00M
- Unknown4.43M
- Unknown4.25M
- Unknown3.82M
- Unknown3.78M
- Unknown2.89M
- Unknown2.50M
- Unknown2.35M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
SNDX Drops After Axatilimab IPF Trial Misses Endpoint
Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.
SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.